ADVA
8.6.2021 09:02:12 CEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its FSP 3000 TeraFlex™ CoreChannel™ , giving internet content providers (ICPs) and communication service providers (CSPs) the power to transmit 800Gbit/s over greater distances than ever before. Using 140GBd sub-carrier technology, the new CoreChannel™ sled offers the market’s longest reach for a single-channel 800Gbit/s solution, enabling ultra-high-capacity transport over existing and new network infrastructure of more than 1,600km. This provides an improvement in reach of over 50% compared with 95GBd technologies. As well as the longest reach, the sled offers the highest client port flexibility. TeraFlex™ CoreChannel™ can support 400GbE, 100GbE and 10GbE or a mixture of client speeds. The solution is now being trialed by major carriers and R&E network operators.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005217/en/
“Network operators across the planet have been harnessing our FSP 3000 TeraFlex™ to unlock the full potential of their fiber assets. Our compact, plug-and-play terminal offers a simple and cost-efficient way to maximize the capacity of optical infrastructure. Today we’re making it even more powerful with the introduction of our CoreChannel™ sled. Customers can now transport data at 400Gbit/s and 800Gbit/s over longer distances than ever before with a solution that delivers the lowest possible cost per bit per kilometer,” said Christoph Glingener, CTO, ADVA. “Our FSP 3000 TeraFlex™ CoreChannel™ technology offers an enormous boost to operators transmitting services across countries and continents. What’s more, long-haul transport with TeraFlex™ CoreChannel™ is even more efficient and reliable thanks to its superior link signal-to-noise (SNR) requirements and higher network performance.”
The launch of ADVA’s CoreChannel™ sled positions the FSP 3000 TeraFlex™ as the industry’s most efficient high-capacity platform for all applications from metro to core to ultra-long-haul submarine links. Compatible with deployed infrastructure, the new solution can transmit 800Gbit/s over more than 1,600km. What’s more, TeraFlex™ CoreChannel™ delivers industry-leading SNR requirements making it resilient to transmission impairments. Along with the bandwidth flexibility and fractional QAM capabilities of the TeraFlex™ terminal, this ensures 800Gbit/s transport with highest efficiency, highest performance and lowest cost. Featuring multi-rate client support, the CoreChannel™ sled can transport any mix of 400GbE, 100GbE and 10GbE services, providing customers with flexibility and protecting their investment as they migrate to higher speeds.
“The launch of our FSP 3000 TeraFlex™ CoreChannel™ changes the game for terrestrial long-haul and regional transport. It gives ICPs and CSPs the ability to inject new capacity into their deployed networks. Now they can drive line speeds of up to 800Gbit/s over distances 50% longer than can be achieved with 95GBd solutions. That advantage will be key to tackling ever-increasing data growth without adding significant cost and complexity,” commented Cornelius Fürst, director, product line management, ADVA. “With its unrivaled reach, multi-rate client flexibility and rich performance settings, TeraFlex™ CoreChannel™ redefines the economics of backbone networks. It will play a key role in accelerating the delivery of high-bandwidth, feature-rich services over ultra-long-haul global infrastructure. And because it can be flexibly configured for lower data rates, it supports a smooth transition to high-speed connectivity.”
Watch this video for more information on the FSP 3000 TeraFlex™ CoreChannel™ : https://adva.li/fsp-3000-teraflex-corechannel-product-video .
Further details are also available in this Tech Cam video: https://adva.li/fsp-3000-teraflex-corechannel-tech-cam .
Supporting slides can be viewed here: https://adva.li/fsp-3000-teraflex-corechannel-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005217/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom